Abstract
Neridronate is a third generation bisphosphonate with established efficacy in metabolic bone disease. In this randomized, open-label study, 118 adults with β-thalassaemia and bone mineral density (BMD) Z scores ≤-2·0 were randomized 1:1-500 mg calcium with 400 international unis (iu) vitamin D daily or 500 mg calcium with 400 iu vitamin D daily plus neridronate 100 mg intravenously every 90 d. Significant increases in BMD at the lumbar spine and total hip were noted in the neridronate group at 6 and 12 months from baseline (P <0·001), and values were significantly higher than the control group at both time intervals. Neridronate also significantly decreased serum bone alkaline phosphatase and C-telopeptide of collagen type 1 levels from as early as 3 months (P = 0·04 and P <0·001, respectively), reaching significantly lower values at 12 months compared with the control group (P <0·05). Reductions in back pain and analgesic use were also evident, starting 3 months from commencing treatment. Treatment was well tolerated by all patients. In this largest randomized trial in thalassaemia-induced osteoporosis to date, neridronate was safe and effective in reducing bone resorption and increasing BMD. The associated reduction in back pain and improved quality of life will encourage adherence to therapy. (Clinicaltrials.gov identifier NCT01140321).
| Original language | English |
|---|---|
| Pages (from-to) | 274-282 |
| Number of pages | 9 |
| Journal | British Journal of Haematology |
| Volume | 158 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Jul 2012 |
Fingerprint
Keywords
- Bisphosphonates
- Bone mineral density
- Osteoporosis
- Pain
- Thalassaemia
ASJC Scopus subject areas
- Hematology
Cite this
Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis : Results from a phase 2, randomized, parallel-arm, open-label study. / Forni, Gian Luca; Perrotta, Silverio; Giusti, Andrea; Quarta, Giovanni; Pitrolo, Lorella; Cappellini, Maria Domenica; D'Ascola, Domenico Giuseppe; Borgna Pignatti, Caterina; Rigano, Paolo; Filosa, Aldo; Iolascon, Giovanni; Nobili, Bruno; Baldini, Marina; Rosa, Alessandra; Pinto, Valeria; Palummeri, Ernesto.
In: British Journal of Haematology, Vol. 158, No. 2, 07.2012, p. 274-282.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis
T2 - Results from a phase 2, randomized, parallel-arm, open-label study
AU - Forni, Gian Luca
AU - Perrotta, Silverio
AU - Giusti, Andrea
AU - Quarta, Giovanni
AU - Pitrolo, Lorella
AU - Cappellini, Maria Domenica
AU - D'Ascola, Domenico Giuseppe
AU - Borgna Pignatti, Caterina
AU - Rigano, Paolo
AU - Filosa, Aldo
AU - Iolascon, Giovanni
AU - Nobili, Bruno
AU - Baldini, Marina
AU - Rosa, Alessandra
AU - Pinto, Valeria
AU - Palummeri, Ernesto
PY - 2012/7
Y1 - 2012/7
N2 - Neridronate is a third generation bisphosphonate with established efficacy in metabolic bone disease. In this randomized, open-label study, 118 adults with β-thalassaemia and bone mineral density (BMD) Z scores ≤-2·0 were randomized 1:1-500 mg calcium with 400 international unis (iu) vitamin D daily or 500 mg calcium with 400 iu vitamin D daily plus neridronate 100 mg intravenously every 90 d. Significant increases in BMD at the lumbar spine and total hip were noted in the neridronate group at 6 and 12 months from baseline (P <0·001), and values were significantly higher than the control group at both time intervals. Neridronate also significantly decreased serum bone alkaline phosphatase and C-telopeptide of collagen type 1 levels from as early as 3 months (P = 0·04 and P <0·001, respectively), reaching significantly lower values at 12 months compared with the control group (P <0·05). Reductions in back pain and analgesic use were also evident, starting 3 months from commencing treatment. Treatment was well tolerated by all patients. In this largest randomized trial in thalassaemia-induced osteoporosis to date, neridronate was safe and effective in reducing bone resorption and increasing BMD. The associated reduction in back pain and improved quality of life will encourage adherence to therapy. (Clinicaltrials.gov identifier NCT01140321).
AB - Neridronate is a third generation bisphosphonate with established efficacy in metabolic bone disease. In this randomized, open-label study, 118 adults with β-thalassaemia and bone mineral density (BMD) Z scores ≤-2·0 were randomized 1:1-500 mg calcium with 400 international unis (iu) vitamin D daily or 500 mg calcium with 400 iu vitamin D daily plus neridronate 100 mg intravenously every 90 d. Significant increases in BMD at the lumbar spine and total hip were noted in the neridronate group at 6 and 12 months from baseline (P <0·001), and values were significantly higher than the control group at both time intervals. Neridronate also significantly decreased serum bone alkaline phosphatase and C-telopeptide of collagen type 1 levels from as early as 3 months (P = 0·04 and P <0·001, respectively), reaching significantly lower values at 12 months compared with the control group (P <0·05). Reductions in back pain and analgesic use were also evident, starting 3 months from commencing treatment. Treatment was well tolerated by all patients. In this largest randomized trial in thalassaemia-induced osteoporosis to date, neridronate was safe and effective in reducing bone resorption and increasing BMD. The associated reduction in back pain and improved quality of life will encourage adherence to therapy. (Clinicaltrials.gov identifier NCT01140321).
KW - Bisphosphonates
KW - Bone mineral density
KW - Osteoporosis
KW - Pain
KW - Thalassaemia
UR - http://www.scopus.com/inward/record.url?scp=84863468463&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863468463&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2141.2012.09152.x
DO - 10.1111/j.1365-2141.2012.09152.x
M3 - Article
VL - 158
SP - 274
EP - 282
JO - British Journal of Haematology
JF - British Journal of Haematology
SN - 0007-1048
IS - 2
ER -